Lunit SCOPE uIHC

Lunit SCOPE uIHC is an AI-powered digital pathology image analysis software designed to transform immunohistochemistry (IHC) biomarker strategy across oncology research and drug development. Trained on over 18 IHC stains spanning more than 20 primary tumor origins, it enables biopharma teams to quantify and characterize protein expression at subcellular, cellular, and whole-slide levels—supporting everything from early translational research to companion diagnostic (CDx) development. The platform is intended for research use only and is not for use in diagnostic procedures or decisions.

Lunit SCOPE uIHC is built for biopharma companies seeking to accelerate biomarker discovery, identify high-value drug targets, and optimize clinical trial strategies. By combining continuous scoring, spatial mapping, and pattern recognition, the software delivers precise, scalable IHC analysis across a wide range of cancer types and development stages.

Core Capabilities

• Continuous staining intensity quantification (0–100%) at the individual cell and subcellular component level.
• Subcellular localization of target expression, distinguishing membrane, cytoplasm, and nucleus compartments.
• Cell type identification, including tumor cells, lymphocytes, and other cell populations.
• Advanced biomarker analysis integrating quantitative intensity measurement, spatial profiling, and pattern recognition—applied individually or in combination to generate robust insights.
• Interactive visualizer enabling real-time intensity cut-off assessment for flexible scoring exploration.

Key Use Cases Across Oncology Development

• Translational research: Supports comprehensive IHC biomarker analysis even in early development stages, capturing a deeper understanding of target expression at subcellular, cellular, and whole-slide levels to inform biomarker advancement.
• CDx development for next-generation IHC biomarkers: Leverages AI-powered analysis—including subcellular localization, continuous scoring, spatial mapping, and ultra-low detection—to develop innovative biomarkers, scoring methods, and cut-offs tailored to a therapy's mechanism of action.
• Target validation and antibody optimization: Identifies drug targets with high tumor and membrane specificity through scalable IHC analysis, surfaceome profiling, and insights that support target selection and therapeutic design.

Drug Target Identification Features

• Surfaceome profiling to characterize cell-surface protein expression landscapes.
• Tumor-specificity analysis to distinguish target expression in tumor versus non-tumor tissue.
• Membrane specificity analysis to support the identification of high-value targets for antibody-based therapeutics.

Lunit SCOPE uIHC is built for end-to-end CDx development with mature regulatory capabilities and broad compatibility across scanners, file types, and digital pathology platforms. The software supports scalable deployment through CRO partnerships—including a global alliance with CellCarta—enabling biopharma teams to access AI-driven IHC analysis across clinical trial workflows. Lunit's deep expertise, robust clinical evidence base, and integration with a wide range of image management systems further differentiate the platform as a partner in AI-powered precision oncology.